CANF - 1.34 Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19 https://stockcharts.com/c-sc/sc?s=CANF&p=D&b=5&g=0&i=t95597984982&r=1540986966849